YouTube Facebook LinkedIn Google+ Twitter Xingrss  

July-August Briefs


Protein-Protein Aggregation Prediction 

Accelrys is hoping to boost scientific collaboration and efficiency, as well as address a major challenge in the development of biotherapeutics with the latest release of Discovery Studio. The new release incorporates what Accelrys says is the first commercially available software for predicting protein-protein aggregation to advance biotherapeutics research. It enables protein engineers to identify the location of regions on antibodies prone to aggregation and then predict substitutions to improve molecular stability.  

South African Pharmacogenomics 

The Centre for Proteomic and Genomic Research (CPGR) in South Africa has joined forces with the Division of Human Genetics at the University of Cape Town (UCT), and the Pharmacogenomics for Every Nation Initiative (PGENI), to map genetic traits underlying the efficacy of drug treatments in Southern African populations. The collaboration will form a regional PGENI Centre of Excellence and, following a pilot phase, hopes to conduct large-scale pharmacogenetic studies to correlate the prevalence of DNA polymorphic traits in local populations with the efficacy of commonly prescribed drugs.

Patient Reporting Predictions 

PHT Corporation is freely disseminating its ePRO Modality Tool, which enables sponsors and CROs to determine which of  five methods—smartphone, tablet, Internet, digital pen and hand held device— is most effective for collecting ePRO data based on their specific study protocol and questionnaires. By publishing the tool and lifting all previous restrictions for its use, PHT hopes to promote further ePRO adoption.   

This story also appeared in the 2011 July-August issue of Bio-IT World magazine.

View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.